• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Adagene Inc.

    11/7/24 4:32:13 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADAG alert in real time by email
    SC 13G/A 1 d882300dsc13ga.htm SC 13G/A SC 13G/A

     

     

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*

     

     

    Adagene Inc.

    (Name of Issuer)

    Ordinary Shares

    (Title of Class of Securities)

    005329 107**

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    **

    There is no CUSIP number assigned to the ordinary shares. CUSIP number 005329 107 has been assigned to the American depositary shares (“ADSs”) of the Issuer, which are quoted on NASDAQ Stock Market under the symbol “ADAG.” Each ADS represents one and one quarter ordinary shares, par value US$0.0001 per share.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. G1933S101    Schedule 13G    Page 1 of 9

     

     1   

     Names of Reporting Persons

     

     Panacea Venture Healthcare Fund II, L.P.

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     4,015,000

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     4,015,000

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     4,015,000

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     7.3%

    12  

     Type of Reporting Person

     

     PN


    CUSIP No. 005329 107    Schedule 13G    Page 2 of 9

     

     1   

     Names of Reporting Persons

     

     Panacea Venture Healthcare Fund II GP Company, Ltd.

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     4,015,000

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     4,015,000

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     4,015,000

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     7.3%

    12  

     Type of Reporting Person

     

     CO


    CUSIP No. 005329 107    Schedule 13G    Page 3 of 9

     

     1   

     Names of Reporting Persons

     

     Panacea Innovation Limited

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     4,015,000

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     4,015,000

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     4,015,000

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     7.3%

    12  

     Type of Reporting Person

     

     CO


    CUSIP No. 005329 107    Schedule 13G    Page 4 of 9

     

     1   

     Names of Reporting Persons

     

     James Huang

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Republic of China

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     4,015,000

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     4,015,000

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     4,015,000

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     7.3%

    12  

     Type of Reporting Person

     

     IN


    CUSIP No. 005329 107    Schedule 13G    Page 5 of 9

     

    ITEM 1.

    (a) Name of Issuer:

    Adagene Inc. (the “Issuer”).

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    4F, Building C14, No. 218

    Xinghu Street, Suzhou Industrial Park

    Suzhou, Jiangsu Province, 215123

    People’s Republic of China

     

    ITEM 2.

    (a) Name of Person Filing:

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

    Panacea Venture Healthcare Fund II, L.P.

    Panacea Venture Healthcare Fund II GP Company, Ltd.

    Panacea Innovation Limited

    James Huang

     

      (b)

    Address of Principal Business Office:

    The business address of each of the Reporting Persons is c/o Maples Corporate Services Limited, Ugland House, Grand Cayman KY1-1104, Cayman Islands.

     

      (c)

    Citizenship of each Reporting Person is:

    Mr. Huang is a citizen of the Republic of China. The remaining Reporting Persons are organized under the laws of the Cayman Islands.

     

      (d)

    Title of Class of Securities:

    Ordinary Shares, par value $0.0001 per share (“Ordinary Shares”)

     

      (e)

    CUSIP Number:

    There is no CUSIP number assigned to the ordinary shares. CUSIP number 005329 107 has been assigned to the American depositary shares (“ADSs”) of the Issuer, which are quoted on NASDAQ Stock Market under the symbol “ADAG.” Each ADS represents one and one quarter ordinary shares, par value US$0.0001 per share.

     

    ITEM 3.

    Not applicable.


    CUSIP No. 005329 107    Schedule 13G    Page 6 of 9

     

    ITEM 4.

    Ownership.

    (a-c)

    The ownership information presented below represents beneficial ownership of Ordinary Shares as of the date of this filing, based upon 55,338,480 Ordinary Shares outstanding as of June 30, 2024, as disclosed in the Issuer’s Current Report on Form 6-K, filed with the Securities and Exchange Commission on July 25, 2024.

     

    Reporting Person   

    Amount

    beneficially

    owned

        

    Percent

    of class:

        Sole
    power
    to vote
    or to
    direct
    the vote:
         Shared
    power to
    vote or to
    direct the
    vote:
        

    Sole
    power to
    dispose or
    to direct
    the
    disposition

    of:

        

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     

    Panacea Venture Healthcare Fund II, L.P.

         4,015,000        7.3 %      0        4,015,000        0        4,015,000  

    Panacea Venture Healthcare Fund II GP Company, Ltd.

         4,015,000        7.3 %      0        4,015,000        0        4,015,000  

    Panacea Innovation Limited

         4,015,000        7.3 %      0        4,015,000        0        4,015,000  

    James Huang

         4,015,000        7.3 %      0        4,015,000        0        4,015,000  

    Panacea Venture Healthcare Fund II, L.P. is the record holder of the Ordinary Shares reported herein.

    James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd., which is the general partner of Panacea Venture Healthcare Fund II, L.P. As a result, each of the Reporting Persons may be deemed to share beneficial ownership of the Ordinary Shares directly reported herein, but each disclaims such beneficial ownership.

     

    ITEM 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    ITEM 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    ITEM 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    ITEM 8.

    Identification and Classification of Members of the Group.

    Not applicable.


    CUSIP No. 005329 107    Schedule 13G    Page 7 of 9

     

    ITEM 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    ITEM 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.


    CUSIP No. 005329 107    Schedule 13G    Page 8 of 9

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: November 7, 2024

     

    Panacea Venture Healthcare Fund II, L.P.
    By: Panacea Venture Healthcare Fund II GP Company, Ltd., its general partner
    By: Panacea Innovation Limited, its sole owner
    By:   /s/ James Huang
    Name:   James Huang
    Title:   Founding Managing Partner
    Panacea Venture Healthcare Fund II GP Company, Ltd.
    By: Panacea Innovation Limited, its sole owner
    By:   /s/ James Huang
    Name:   James Huang
    Title:   Founding Managing Partner
    Panacea Innovation Limited
    By:   /s/ James Huang
    Name:   James Huang
    Title:   Founding Managing Partner
    James Huang
    /s/ James Huang


    CUSIP No. 005329 107    Schedule 13G    Page 9 of 9

     

    LIST OF EXHIBITS

     

    Exhibit No.   

    Description

    99    Joint Filing Agreement (previously filed).
    Get the next $ADAG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADAG

    DatePrice TargetRatingAnalyst
    1/31/2025Overweight → Equal-Weight
    Morgan Stanley
    2/1/2022$27.00 → $15.00Overweight
    Morgan Stanley
    More analyst ratings

    $ADAG
    SEC Filings

    See more
    • Amendment: SEC Form F-3/A filed by Adagene Inc.

      F-3/A - Adagene Inc. (0001818838) (Filer)

      5/23/25 4:06:11 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Adagene Inc.

      6-K - Adagene Inc. (0001818838) (Filer)

      5/22/25 5:05:23 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Adagene Inc.

      SCHEDULE 13G/A - Adagene Inc. (0001818838) (Subject)

      5/15/25 5:29:08 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADAG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Adagene downgraded by Morgan Stanley

      Morgan Stanley downgraded Adagene from Overweight to Equal-Weight

      1/31/25 8:29:36 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley reiterated coverage on Adagene with a new price target

      Morgan Stanley reiterated coverage of Adagene with a rating of Overweight and set a new price target of $15.00 from $27.00 previously

      2/1/22 9:41:00 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADAG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Adagene Inc.

      SC 13G/A - Adagene Inc. (0001818838) (Subject)

      11/7/24 4:32:13 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Adagene Inc. (Amendment)

      SC 13D/A - Adagene Inc. (0001818838) (Subject)

      3/1/24 4:30:20 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Adagene Inc. (Amendment)

      SC 13G/A - Adagene Inc. (0001818838) (Subject)

      2/9/24 8:35:54 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADAG
    Leadership Updates

    Live Leadership Updates

    See more
    • Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

      - Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor. "Adagene is currently breaking a toxicity barrier with their proprietary masking technology, delivering a checkpoint inhibitor selectively and conditionally to tumor cells. Their platform has broad potential for enhanced immunotherapy with effective regulatory T-cell depletion, in conjunction with monoclonal antibodies, bispecifics, T-cell engagers, and antibod

      4/28/25 8:00:00 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

      - Global oncology expert brings deep insight in colorectal cancer and role of CTLA-4 therapy as a cornerstone for combination immunotherapy - SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the "SAB"). Dr. Lenz is the Associate Director for Clinical Research and Co-leader of the Translational Science Program at the USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC and Co-Director of the Center for Cancer Drug Development a

      3/7/24 4:01:00 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board

      - Brings deep insight in tumor-specific Treg depletion for anti-CTLA-4 therapies delivered intratumorally to overcome dose dependent toxicities - - Expertise contributes to Adagene's novel anti-CTLA-4 therapies delivered systemically at higher and repeated doses with compelling safety - SAN DIEGO and SUZHOU, China, March 05, 2023 (GLOBE NEWSWIRE) --  Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Professor Aurélien Marabelle, MD, PhD, to its Scientific and Strategic Advisory Board (the "SAB"). Professor Marabelle is a physician-scientist with expertise in oncology and imm

      3/5/23 7:39:30 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADAG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

      CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatellite stable colorectal cancer All six responders in the 20 mg/kg cohorts remain on treatment, with four patients on study for over forty weeks Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, with a median follow-up of 17.8 months and only 1 out of 41 patients was censored due to early withdrawal within the first 12 months SAN DIEGO and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company

      5/22/25 5:05:00 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

      - Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor. "Adagene is currently breaking a toxicity barrier with their proprietary masking technology, delivering a checkpoint inhibitor selectively and conditionally to tumor cells. Their platform has broad potential for enhanced immunotherapy with effective regulatory T-cell depletion, in conjunction with monoclonal antibodies, bispecifics, T-cell engagers, and antibod

      4/28/25 8:00:00 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

      SAN DIEGO and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at ASCO 2025 in Chicago, IL, May 30 - June 3. Abstract Title: Safety and Efficacy of ADG126 (an Anti-CTLA-4 Masking Antibody) in Combination with Pembrolizumab: Updated Results of Phase 1b/2 Study in Advanced MSS CRCDate: Saturday, May 31, 2025Poster Viewing: 9:00 AM-12:00 PM CDTOnsite Location: McCormick Place, Chicago, IL, Board #248Abstract Number: 3579 Poster will be made available on the Publications page of the company's website here. About AdageneAdagene

      4/23/25 10:05:00 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADAG
    Financials

    Live finance-specific insights

    See more
    • Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates

      – Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-1 therapy; results to be presented at SITC 2022 – – Masked, anti-CTLA-4 antibody, ADG126, safely dosed repeatedly up to 20 mg/kg as a single agent with encouraging efficacy signals; results to be presented at ESMO 2022 – – Presentation of combination dosing data with anti-PD-1 therapies in 2022, while dose expansion begins for both ADG116 and ADG126 in targeted tumors – – Submitted regulatory filing for clinical trial of masked, IgG1-based anti-CD137 candidate, ADG206, with greater preclinical potency than the analog of

      8/30/22 5:25:00 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care